Disclosures for "Real-world Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients Living with Generalized Myasthenia Gravis"
-
Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. An immediate family member of Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.
-
Ms. Qi has received personal compensation for serving as an employee of argenx.
-
John Stone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx.
-
Dr. Gelinas has received personal compensation for serving as an employee of argenx. Dr. Gelinas has stock in argenx.
-
Matt Jefferson has received personal compensation for serving as an employee of argenx. Matt Jefferson has stock in argenx.
-
Mr. Suthagar has received personal compensation for serving as an employee of ZS Associates.
-
Mr. Menon has received personal compensation for serving as an employee of ZS Associates.
-
Mr. Goyal has received personal compensation for serving as an employee of ZS Associates.
-
Dr. Phillips has received personal compensation for serving as an employee of argenx. Dr. Phillips has stock in argenx.